Vincristine/irinotecan/temsirolimus upfront window treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 Study Committee

Survival for children with metastatic hepatoblastoma (HB) remains suboptimal. We report the response rate and outcome of two courses of vincristine/irinotecan/temsirolimus (VIT) in children with high‐risk (HR)/metastatic HB.

[1]  W. Grajkowska,et al.  Health Status in Long-Term Survivors of Hepatoblastoma , 2019, Cancers.

[2]  C. Rodríguez-Galindo,et al.  Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee , 2017, Cancer.

[3]  D. Aronson,et al.  Malignant tumors of the liver in children. , 2016, Seminars in pediatric surgery.

[4]  R. Norris,et al.  Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study , 2014, Pediatric blood & cancer.

[5]  B. Morland,et al.  Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study , 2013, The Lancet. Oncology.

[6]  B. Morland,et al.  Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL). , 2012, European journal of cancer.

[7]  H. Katzenstein,et al.  Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategies , 2012, Pediatric blood & cancer.

[8]  Mark L. Greenberg,et al.  Survival and Long-term Outcomes in Children With Hepatoblastoma Treated With Continuous Infusion of Cisplatin and Doxorubicin , 2011, Journal of pediatric hematology/oncology.

[9]  Christie Powell,et al.  Irinotecan as maintenance therapy in high‐risk hepatoblastoma , 2010, Pediatric blood & cancer.

[10]  T. Merchant,et al.  Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group , 2010, Pediatrics.

[11]  G. Tomlinson,et al.  Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors , 2009, Pediatric blood & cancer.

[12]  M. Gaub,et al.  Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis , 2009, Clinical Cancer Research.

[13]  G. Perilongo,et al.  Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. , 2008, European journal of cancer.

[14]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Tee,et al.  Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif* , 2007, Journal of Biological Chemistry.

[16]  O. Ijichi,et al.  Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single‐agent therapy with irinotecan , 2006, Pediatric transplantation.

[17]  W. London,et al.  Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Helman,et al.  CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. , 2006, Neoplasia.

[19]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[20]  Denise Williams,et al.  Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). , 2003, Medical and pediatric oncology.

[21]  Michael N. Hall,et al.  TOR signalling in bugs, brain and brawn , 2003, Nature Reviews Molecular Cell Biology.

[22]  H. Katzenstein,et al.  Novel therapeutic approaches in the treatment of children with hepatoblastoma. , 2002, Journal of pediatric hematology/oncology.

[23]  W. London,et al.  Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. V. von Schweinitz,et al.  Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: A report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94 , 1999, Klinische Padiatrie.

[25]  J. Quinn,et al.  Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Quinn,et al.  Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Childrens Cancer Study Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Wiwanitkit.  Irinotecan as a maintenance therapy for hepatoblastoma: a comment. , 2010, Journal of cancer research and therapeutics.

[28]  Robert Ford,et al.  Individual patient data analysis to assess modifications to the RECIST criteria. , 2009, European journal of cancer.

[29]  R. Abraham.  mTOR as a positive regulator of tumor cell responses to hypoxia. , 2004, Current topics in microbiology and immunology.

[30]  G. Perilongo,et al.  Hepatoblastoma presenting with lung metastases: Treatment results of the first cooperative, prospective study of the International Society of paediatric Oncology on childhood liver tumors , 2000 .

[31]  M. Shipp,et al.  Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. , 1985, Medical and pediatric oncology.